インサイト社の株式は第2四半期に51.4%減少したが,収益は2025年6月までに16.5%上昇し,アナリストは将来について分かれていた. Incyte Corp.'s stake dropped 51.4% in Q2, but revenue rose 16.5% by June 2025, with analysts split on its future.

Incyte Corporation(INCY)は、第2四半期にSovran Advisors LLCによって株式が51.4%減り、778,000ドル相当の11,504株が残り、チェコ国立銀行は保有株を6.4%増やしました。 Incyte Corporation (INCY) saw its stake reduced by Sovran Advisors LLC by 51.4% in Q2, leaving it with 11,504 shares valued at $778,000, while the Czech National Bank increased its holding by 6.4%. 腫瘍学および炎症に対する薬を販売するバイオ医薬品会社は,2025年6月時点で16.46%の収益成長を示し,純利益率33.32%と低い債務対資本比で強い財務状態を維持しています. The biopharmaceutical company, which markets drugs for oncology and inflammation, reported 16.46% revenue growth as of June 2025 and maintains strong financial health with a 33.32% net margin and low debt-to-equity ratio. 分析者は7"買い"10"維持"1"売る"と 混在した評価を提示し 合意は"維持"と 82.53ドルの目標価格です Analysts offer mixed ratings—seven "Buy," ten "Hold," one "Sell"—with a consensus "Hold" and a target price of $82.53. 1600億円の市場キャップを備えた86.53ドルの株式取引, p/E/19.67, β 0.75, 比較的安定性が反映されている. The stock trades at $86.53 with a market cap of $16.90 billion, a P/E of 19.67, and a beta of 0.75, reflecting relative stability.